Pathological complete response achieved with FLOT chemotherapy in two patients with MSI-H esophagogastric junction and gastric adenocarcinoma.

Globally, more than 1 million new cases of gastric cancer were estimated in 2020, ranking fourth in cancer mortality. Currently although in resectable gastric cancer and esophagogastric junction (EGJ) adenocarcinoma a perioperative triplet chemotherapy regimen including a fluoropyrimidine, a platinum compound and docetaxel (FLOT) demonstrated a better overall survival, the survival rate is still very low, and a massive effort is still required to improve clinical prognosis. High microsatellite instability (MSI-H) status in gastric cancer is a favorable prognostic factor but poor data are available on its predictive role for perioperative FLOT chemotherapy in resectable gastric cancer.

Graphitic Carbon Nitride as a Promising Visible-Light-Activated Support Boosting Platinum Nanoparticle Activity in Ethanol Electrooxidation.

In the present work, exfoliated graphitic carbon nitride (g-CN) is immobilized on carbon paper substrates by a simple electrophoretic route, and subsequently decorated with ultra-low amounts (≈μg/cm) of Pt nanoparticles (NPs) by cold plasma sputtering. Optimization of preparative conditions allowed a fine tuning of Pt NPs size, loading and distribution and thus a controlled tailoring of g-CN/Pt interfacial interactions. Modulation of such features yielded g-CN-Pt-based anode materials with appealing activity and stability towards the ethanol oxidation reaction (EOR) in alkaline aqueous solutions, as revealed by electrochemical tests both in the dark and under irradiation.

Prognostic role of sodium levels in colorectal cancer patients receiving aflibercept plus FOLFIRI.

To investigate the impact of natremia in metastatic colorectal cancer (mCRC) patients treated with aflibercept plus folinic acid, 5-fluorouracil, oxaliplatin and irinotecan (FOLFIRI). A total of 84 mCRC patients receiving aflibercept plus FOLFIRI as second-line treatment were enrolled and divided into two groups based on their median sodium value. Progression-free survival and overall survival were analyzed.

Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma.

R-CHOP standard chemotherapy is successful in about 60% of diffuse large B-cell lymphoma (DLBCL) patients. Unresponsive patients have a poor prognosis, and predictive biomarkers of response to R-CHOP are lacking. We conducted the first prospective GWAS study aimed at exploring constitutional biomarkers predictive of R-CHOP efficacy and toxicity.